| |
Number (%)
|
Mean OD (±SD)
|
p-value
|
|---|
|
Pathologic stage
| | | |
|
pT2
|
143 (78.1)
|
0.027 (±0.010)
|
-
|
|
pT3a
|
21 (11.5)
|
0.027 (±0.009)
|
0.77
|
|
pT3b
|
19 (10.4)
|
0.021 (±0.007)
|
0.009
|
|
Gleason score
| | | |
|
≤6, 3 + 4
|
143 (78.1)
|
0.028 (±0.010)
|
-
|
|
4 + 3, ≥8
|
40 (21.9)
|
0.023 (±0.009)
|
0.02
|
|
Preoperative PSA (ng/ml)
| | | |
|
<4
|
24 (13.1)
|
0.026 (±0.011)
|
-
|
|
4–10
|
125 (68.3)
|
0.027 (±0.010)
|
0.84
|
|
>10
|
34 (18.6)
|
0.025 (±0.008)
|
0.87
|
|
Tumor volume
| | | |
|
<10 %
|
40 (22.1)
|
0.026 (±0.011)
|
-
|
|
10–19 %
|
42 (23.2)
|
0.029 (±0.011)
|
0.82
|
|
20–29 %
|
29 (16.0)
|
0.029 (±0.010)
|
0.27
|
|
30–39 %
|
33 (18.2)
|
0.026 (±0.009)
|
0.77
|
|
≥40 %
|
37 (20.4)
|
0.024 (±0.010)
|
0.45
|
|
Recurrence status
| | | |
|
Non-recur
|
125 (68.3)
|
0.028 (±0.011)
|
-
|
|
Recur
|
58 (31.7)
|
0.023 (±0.008)
|
0.001
|
|
Positive margins
| | | |
|
No
|
88 (48.9)
|
0.027 (±0.010)
|
-
|
|
Yes
|
92 (51.1)
|
0.026 (±0.010)
|
0.53
|
|
Lymph node status
| | | |
|
Negative
|
169 (95.5)
|
0.027 (±0.010)
|
-
|
|
Positive
|
8 (4.5)
|
0.022 (±0.009)
|
0.15
|
- Abbreviations: prostate cancer (PCa), prostate-specific antigen (PSA), optical density (OD)
